MarketFriction

ERIS Lifesciences Ltd

NSE ERIS · BSE 540596 · Pharmaceuticals
₹1,189.80 -0.18%
NSE close2026-10-01
52 week range1,180.10 - 1,740.00
Market cap₹16,916 Cr.
P/E25.8
IPO 2017 · +97% since Microcap 250 Price band 20% Delivery 47.4%

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Consolidated, Rs crore
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales505486551720741727705773792807757873
Expenses324311402470477477453496504526484577
Operating Profit181176148250265250252277288282272296
OPM %36%36%27%35%36%34%36%36%36%35%36%34%
Other Income3415254843-1722
Interest161833605957544950494647
Depreciation424654768081777169707072
Profit before tax12611677116129116129161173145159179
Tax %3%12%-4%22%25%25%21%22%22%25%-75%20%
Net Profit12210180909687102125134109279143
EPS in Rs9.077.555.226.126.736.156.898.668.827.3220.3310.28
Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales5977508569821,0741,2121,3471,6852,0092,8943,1293,230
Expenses4254805336377027818581,1461,3321,8762,0092,092
Operating Profit1722693223453724314895396771,0181,1201,138
OPM %29%36%38%35%35%36%36%32%34%35%36%35%
Other Income32526311292292218-9-9
Interest0111232242685231193191
Depreciation20232636504365117183315280281
Profit before tax154270312317331394442405431489639657
Tax %13%9%6%8%11%10%8%8%8%23%-1%
Net Profit135247295291297355406374397375648666
EPS in Rs9,714.1817.9521.3921.1521.8426.1629.8828.1028.8225.8444.7246.75
Dividend Payout %63%0%0%0%13%21%20%26%0%28%16%
10 Years5 Years3 YearsTTM1 YearLast Year
Compounded Sales Growth18%21%23%10%
Compounded Profit Growth17%12%19%69%
Stock Price CAGR%10%12%-23%
Return on Equity21%18%16%19%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital0.140.1414141414141414141414
Reserves2662995538481,1371,2831,5631,8952,1822,5732,8413,889
Borrowings10137717607848772,7812,4782,359
Other Liabilities91981241701752052022333371,3661,415861
Total Liabilities3573976921,4081,5021,5021,7852,2263,4106,7346,7477,123
Fixed Assets72712327717618758549182,5684,3195,3065,188
CWIP000034227222067171
Investments1671903033653567829452037166762
Other Assets1191361572713835446367617832,3791,3071,702
Total Assets3573976921,4081,5021,5021,7852,2263,4106,7346,7477,123
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity901312002352232713753782924861,065538
Cash from Investing Activity-92-44-184-590-5123-323-320-975-1,828-78-369
Cash from Financing Activity0-84-24363-221-335-82-456881,380-881-314
Net Cash Flow-24-88-360-3014538105-145
Free Cash Flow77108150210186125350258-550357910241
CFO/OP96%97%94%94%85%87%103%94%68%87%114%59%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days161624283153424463775879
Inventory Days223178195178196148145166136182171200
Days Payable14292134247200213157166129210170151
Cash Conversion Cycle9710284-4028-123044704859129
Working Capital Days15923-13-1759647550-296-49-71
ROCE %47%53%60%34%26%25%27%25%17%11%12%14%
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters54.91%54.90%54.90%54.88%54.87%54.86%54.85%54.83%54.85%54.85%53.92%54.14%
FIIs13.20%13.13%14.27%14.59%8.01%8.36%8.43%8.39%7.21%6.85%6.39%5.76%
DIIs14.52%14.55%15.63%16.23%18.64%18.07%18.07%18.18%19.36%20.31%20.35%20.71%
Public17.37%17.41%15.20%14.30%18.47%18.73%18.64%18.59%18.57%17.97%19.33%19.39%
No. of Shareholders42,24546,49651,75344,17646,34653,31450,08752,22559,43854,71351,65650,798

Fundamentals

Market Cap₹ 16,916 Cr.
Current Price₹ 1,219
Stock P/E25.8
Book Value₹ 282
ROCE14.1 %
ROE18.7 %
Dividend Yield0.59 %
Face Value₹ 1.00
Compounded Sales Growth (TTM)10%
Compounded Profit Growth (TTM)69%
Consolidated figures.
Valuation
Market capRs 16,484 Cr
Enterprise valueRs 18,775 Cr
P/E (TTM)25.60x
Price to book4.22x
Price to sales5.10x
EV / EBITDA16.64x
EV / EBIT22.15x
EV / sales5.81x
Price to cash flow30.64x
Earnings yield3.91%
Dividend yield0.61%
P/E, 3-year average37.71x
P/B, 3-year average5.27x
P/E, 5-year average31.31x
P/B, 5-year average4.85x
Profitability
Operating margin (excl. other income)35.79%
Operating margin (incl. other income)35.49%
EBITDA margin34.95%
Pre-tax margin20.34%
Net profit margin19.94%
Net margin, latest quarter16.31%
ROE18.34%
ROCE14.34%
ROA8.93%
ROE, 3-year average15.89%
ROCE, 3-year average13.34%
ROA, 3-year average7.29%
ROE, 5-year average17.92%
ROCE, 5-year average16.40%
ROA, 5-year average11.14%
ROIC (approx.)13.88%
Tax rate-1.40%
Other income / net worth-0.24%
Growth
Sales growth (latest year)8.15%
Profit growth (latest year)76.08%
Sales CAGR, 3 years22.92%
Sales CAGR, 5 years20.89%
Profit CAGR, 3 years17.47%
Profit CAGR, 5 years11.77%
Sales growth QoQ15.42%
Profit growth QoQ-49.44%
Sales growth YoY (latest quarter)12.97%
Profit growth YoY (latest quarter)20.68%
Per share
EPS (TTM)Rs 46.48
EPS (latest year)Rs 44.72
EPS (latest quarter)Rs 10.28
EPS, 3-year averageRs 33.13
EPS, 5-year averageRs 31.47
Book value per shareRs 281.69
Sales per shareRs 233.12
Cash flow per shareRs 38.83
Free cash flow per shareRs 17.40
Dividend per share (latest year)Rs 7.21
Dividend per share, 3-year averageRs 7.28
Dividend per share, 5-year averageRs 6.98
Dividends
Dividend payout16.12%
Dividend payout, 3-year average22.29%
Dividend payout, 5-year average22.71%
Efficiency
Asset turnover0.44x
Fixed asset turnover0.60x
Inventory turnover2.03x
Inventory days180 days
Debtor days79 days
Debtors turnover4.60x
Creditor days151 days
Cash conversion cycle129 days
Working capital days-71 days
Leverage
Total debtRs 2,359 Cr
Cash and bankRs 67 Cr
Net debtRs 2,291 Cr
Debt to equity0.60x
Net debt / EBITDA2.03x
Interest coverage4.45x
Current ratio (filing 2026-03-31)0.74x
Quick ratio (filing 2026-03-31)0.53x
Trade payables (filing 2026-03-31)Rs 330 Cr
Owners' fund to total sources54.79%
Debt to assets33.11%
Cash flow
Cash from Operating Activity (latest year)Rs 538 Cr
Cash from Investing Activity (latest year)Rs -369 Cr
Cash from Financing Activity (latest year)Rs -314 Cr
Net Cash Flow (latest year)Rs -145 Cr
Free cash flow (latest year)Rs 241 Cr
FCFE (approx.: FCF + change in debt)Rs 122 Cr
Cash from ops / profit, 5 years1.25x
Sales to cash flow5.82x
Statement figures
Net sales (TTM)Rs 3,230 Cr
Net sales (latest year)Rs 3,129 Cr
Sales (latest quarter)Rs 873 Cr
Operating profit excl. other income (latest year)Rs 1,120 Cr
Operating profit (latest quarter)Rs 296 Cr
Other income (TTM)Rs -9 Cr
EBITDA (TTM)Rs 1,129 Cr
PBDT (TTM)Rs 938 Cr
Profit before tax (TTM)Rs 657 Cr
Tax (latest year)Rs -9 Cr
Net profit (TTM)Rs 644 Cr
Net profit (latest year)Rs 620 Cr
Net profit (latest quarter)Rs 142 Cr
Depreciation (TTM)Rs 281 Cr
Depreciation (latest quarter)Rs 72 Cr
Interest (TTM)Rs 191 Cr
Cost of goods sold (latest year)Rs 885 Cr
Total expenditure (latest year)Rs 2,009 Cr
Total income (latest year)Rs 3,120 Cr
Share capitalRs 14 Cr
ReservesRs 3,889 Cr
Shareholders' fundsRs 3,903 Cr
Total assetsRs 7,123 Cr
Net blockRs 5,188 Cr
Capital work in progressRs 171 Cr
InvestmentsRs 62 Cr
ReceivablesRs 680 Cr
InventoryRs 437 Cr
Other liabilitiesRs 861 Cr
Shares outstanding (crore)13.85
Ownership
Promoter holding54.14% (-0.69 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
P/E 25.6 is at the 28th percentile of its own 9.4-year range (median 30.3, low 17.6, high 70.7).
P/B 4.22 is at the 1th percentile (median 6.30).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
PeriodERISNifty 50Difference
1 week-6.7%-2.8% -3.9 pts
1 month-8.5%-6.8% -1.7 pts
3 months-16.9%-7.6% -9.2 pts
6 months-8.3%+0.4% -8.7 pts
1 year-26.8%-9.9% -16.9 pts
2 years-10.2%-13.6% +3.4 pts
3 years+35.8%+14.2% +21.6 pts
5 years+55.0%+27.9% +27.1 pts
84 mutual fund schemes hold about ₹3,231 Cr. Over three months 48 bought more and 10 sold (share counts, price move removed).
FundWeightEst. Cr3m shares
HDFC Small Cap Fund2.00%839 +3%
HDFC Aggressive Hybrid Fund1.43%319 +9%
Franklin India Small Cap Fund1.97%290 +6%
Franklin India Flexi Cap Fund0.94%183 +8%
DSP Small Cap Fund0.74%160 -1%
HSBC Small Cap Fund0.53%101 +2%
UTI Flexi Cap Fund0.39%94 -2%
Mirae Asset Healthcare Fund2.55%91 -3%
HDFC Multi Cap Fund0.43%88 +7%
HDFC Large & Mid Cap Fund0.29%88 +5%
Bandhan Small Cap Fund0.22%76 -7%
UTI Small Cap Fund1.31%69 +4%
Franklin India ELSS Tax Saver Fund0.97%60 +8%
Franklin India Multi Cap Fund1.12%59 -9%
HSBC Value Fund0.38%58 +5%
Mirae Asset Aggressive Hybrid Fund0.53%51 +7%
Aditya Birla SL Aggressive Hybrid Fund0.68%49 +7%
HDFC Business Cycle Fund1.76%49 +6%
HDFC Manufacturing Fund0.46%49 +5%
Bank of India Small Cap Fund1.32%44 -1%
HDFC Pharma and Healthcare Fund1.06%35 -14%
Franklin India Multi Asset Allocation Fund1.09%32 +6%
Bank of India Multi Cap Fund2.21%29 +7%
DSP Healthcare Fund0.76%29 +100%
HSBC Aggressive Hybrid Fund0.45%26 +5%

Red flags

F-score 6 of 8
explainReceivables outrunning sales Receivables grew 48% vs sales +8% in 2026
lookRegulator order or action Regulator order or action 2026-05-28: Eris Lifesciences Limited has informed the Exchange about Action(s) taken or orders passed
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Latest quarter

Jun 2026
Sales ₹873 Cr +12.9% vs Jun 2025. Net profit ₹143 Cr +14.4%.
Against our estimate for Jun 2026: sales +3.4%, profit +2.4% in line. Our estimate for Sep 2026: sales Rs 872 Cr, profit Rs 145 Cr (how).

Activity

Compare
CompanyMcap (Cr)P/EROCE
Sun Pharmaceutical Industries Ltd447,47635.420.5 %
Divis Laboratories Ltd250,36384.022.0 %
Torrent Pharmaceuticals Ltd186,15283.415.2 %
Zydus Lifesciences Ltd119,75024.621.1 %
Cipla Ltd111,43031.115.5 %
Laurus Labs Ltd106,92897.817.8 %
Mankind Pharma Ltd105,12049.313.5 %
Dr Reddys Laboratories Ltd104,49432.413.0 %
Aurobindo Pharma Ltd97,68225.812.9 %
Lupin Ltd93,84015.829.9 %
Glenmark Pharmaceuticals Ltd68,90522.139.8 %
Alkem Laboratories Ltd62,77227.621.2 %
Biocon Ltd61,43984.53.61 %
Abbott India Ltd57,94935.944.8 %
Gland Pharma Ltd49,33343.115.1 %
No bulk or block deals on record.
Ex-dateActionFactor
2026-05-29Interim Dividend - Rs 7.21 Per Share
2025-02-13Interim Dividend - Rs 7.35 Per Share
2024-09-17Annual General Meeting
2023-09-15Annual General Meeting
2022-08-23Annual General Meeting
2022-08-11Interim Dividend- Rs 7.35 Per Share
2021-08-23 Annual General Meeting
2021-08-05 Interim Dividend - Rs 6.01 Per Share
2020-09-18 Annual General Meeting
2020-08-13 Interim Dividend - Rs 5.50 Per Share
2020-03-19 Interim Dividend - Rs 2.87 Per Share
2019-09-18 Annual General Meeting
2019-07-12 Buyback
2018-09-19 Annual General Meeting
2017-09-20 Annual General Meeting
DateTypeWhat it says
2026-09-25Shareholder meetingVoting results.
2026-09-25Shareholder meetingProceedings of Annual General Meeting held on September 25, 2026
2026-09-22AllotmentAllotment of 155264 securities pursuant to ESOP/ESPS at its meeting held on September 22, 2026
2026-09-21AppointmentAppointment of Mr as Non- Executive Independent Director of the company w.e.f. September 26, 2026.
2026-09-11ResignationResignation of Mr Krishnakumar Vaidyanathan as Executive Director of the company w.e.f. September 30, 2026.
2026-09-10Rumour Verification - RegulaRumour Verification - Regulation 30(11)
2026-09-09AgreementsLoan Agreement
2026-09-07Concall / analyst meetSchedule of meet
2026-09-02Shareholder meetingNotice of Annual General Meeting to be held on September 25, 2026
2026-08-31Board meeting outcomeOutcome of Board Meeting held on August 31, 2026.
2026-08-24Concall / analyst meetSchedule of meet
2026-08-12Concall / analyst meetSchedule of meet
2026-08-10Concall / analyst meetSchedule of meet
2026-08-06AgreementsLoan Agreement.
2026-08-04Concall / analyst meetTranscript
2026-07-30Concall / analyst meetSchedule of meet
2026-07-30ESOPAllotment of 4816 Shares.
2026-07-29Concall / analyst meetLink of Recording
2026-07-29Investor PresentationInvestor Presentation
2026-07-29Board meeting outcomeEris Lifesciences Limited has submitted to the Exchange, the financial results for the period ended June 30, 2026.
2026-07-23Concall / analyst meetSchedule of meet
2026-06-26ESOPAllotment of 11233 Shares.
2026-06-23UpdatesCorporate presentation.
2026-06-08UpdatesPayment made of theinterest to the holders of Non-convertible Debentures.
2026-05-28Regulatory actionAction(s) taken or orders passed
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.

Quick answers

What is the market cap of ERIS Lifesciences Ltd?

ERIS Lifesciences Ltd (ERIS) has a market capitalisation of Rs 16,916 Cr. at the 2026-10-01 close.

What is the P/E ratio of ERIS Lifesciences Ltd?

ERIS Lifesciences Ltd trades at a P/E of 25.8 on trailing twelve-month profit, at the 2026-10-01 close.

What were ERIS Lifesciences Ltd's latest quarterly results?

In the Jun 2026 quarter, ERIS Lifesciences Ltd sales was Rs 873 Cr (+12.9% vs Jun 2025) and net profit was Rs 143 Cr.

What is the 52-week high and low of ERIS Lifesciences Ltd?

The 52-week high is Rs 1,740.00 and the 52-week low is Rs 1,180.10.

Data: NSE and BSE daily reports, company filings. Numbers only, not investment advice, not a SEBI-registered research service.AboutMethodologyFAQResearchContactTermsPrivacyDisclaimerUpdated 2026-10-03